CORDIS
EU research results

CORDIS

English EN

Targeting the tumour microenvironment to improve pancreatic cancer prognosis

Project information

Grant agreement ID: 256974

Status

Closed project

  • Start date

    1 February 2011

  • End date

    31 July 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 4 230 298,46

  • EU contribution

    € 3 000 000

Coordinated by:

PHILIPPS UNIVERSITAET MARBURG

Germany

Objective

Pancreatic cancer is one of the most lethal human cancers with a five-year survival rate of less than 5%. Late presentation and a high level of resistance to chemotherapeutic drugs are among the major reasons for this dismal prognosis. The presence of the highest degree of desmoplasia among all solid tumours and the fact that chronic inflammatory pancreatic disease is associated with an increased risk for pancreatic cancer indicate, that the tumour microenvironment is of particular importance for carcinogenesis in the pancreas. The long-term objective of this proposal is to increase survival of pancreatic cancer patients by exploring the contribution of the tumour microenvironment to the failure of presently available oncological treatments. For this purpose the clinical observation will be reverse-translated into innovative in-vitro and mouse models closely mimicking the human disease. This will allow a profound study of the mechanistic basis of treatment failure by deciphering the complex network between components of the microenvironment and cancer cells leading to increased resistance to chemotherapy and infiltrative growth along adjacent lymphatic and neural structures as well as metastatic spread. Identification of cancer (stem) cell-autonomous as well as stromal-derived mediators of invasion and chemoresistance will lead to novel drug targets to overcome the current therapeutic dilemma. The consortium has been specifically designed to include all required levels of expertise: 1) surgical and medical oncology groups conducting the largest clinical trials for pancreatic cancer in Europe, 2) expert pancreatic pathologists, 3) basic scientists focused on the study of carcinogenesis and tumour microenvironment interactions in the pancreas, 4) molecular oncology groups that have developed genetically engineered mouse models faithfully recapitulating human pancreatic cancer, as well as 5) pharmaceutical industry specialised on drug development.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

PHILIPPS UNIVERSITAET MARBURG

Address

Biegenstrasse 10
35037 Marburg

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 626 777

Administrative Contact

Sandra Basenau (Ms.)

Participants (16)

THE UNIVERSITY OF LIVERPOOL

United Kingdom

EU Contribution

€ 248 800

FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III

Spain

EU Contribution

€ 550 000

UNIVERSITA DEGLI STUDI DI VERONA

Italy

EU Contribution

€ 145 000

UNIVERSITAET GREIFSWALD

Germany

EU Contribution

€ 270 000

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 207 560

Axcentua Pharmaceuticals AB

Sweden

EU Contribution

€ 72 440

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN

Germany

EU Contribution

€ 131 400

Bayer Pharma AG

Germany

EU Contribution

€ 76 462

CANCER RESEARCH UK LBG

United Kingdom

EU Contribution

€ 144 365

LAB 21 LIMITED

United Kingdom

EU Contribution

€ 20 758

Fondazione Centro San Raffaele

Italy

EU Contribution

€ 60 000

UNIVERSITA DEGLI STUDI DI TORINO

Italy

EU Contribution

€ 60 000

NATIMAB THERAPEUTICS SRL

Italy

EU Contribution

€ 45 000

Concentris Research Management GmbH

Germany

EU Contribution

€ 202 838

TECHNISCHE UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 138 600

FONDAZIONE CENTRO SAN RAFFAELE

Italy

Project information

Grant agreement ID: 256974

Status

Closed project

  • Start date

    1 February 2011

  • End date

    31 July 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 4 230 298,46

  • EU contribution

    € 3 000 000

Coordinated by:

PHILIPPS UNIVERSITAET MARBURG

Germany